BR112017010440A2 - administração sublingual de riluzol - Google Patents

administração sublingual de riluzol

Info

Publication number
BR112017010440A2
BR112017010440A2 BR112017010440A BR112017010440A BR112017010440A2 BR 112017010440 A2 BR112017010440 A2 BR 112017010440A2 BR 112017010440 A BR112017010440 A BR 112017010440A BR 112017010440 A BR112017010440 A BR 112017010440A BR 112017010440 A2 BR112017010440 A2 BR 112017010440A2
Authority
BR
Brazil
Prior art keywords
riluzole
sublingual administration
sublingual
sublingual formulation
administration
Prior art date
Application number
BR112017010440A
Other languages
English (en)
Portuguese (pt)
Inventor
M Berman Robert
Coric Vladimir
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of BR112017010440A2 publication Critical patent/BR112017010440A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112017010440A 2014-11-21 2015-11-17 administração sublingual de riluzol BR112017010440A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (1)

Publication Number Publication Date
BR112017010440A2 true BR112017010440A2 (pt) 2017-12-26

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010440A BR112017010440A2 (pt) 2014-11-21 2015-11-17 administração sublingual de riluzol

Country Status (14)

Country Link
US (1) US20180153862A1 (enExample)
EP (1) EP3220890A1 (enExample)
JP (1) JP2017535612A (enExample)
KR (1) KR20170137030A (enExample)
CN (1) CN107735077A (enExample)
AU (1) AU2015350142A1 (enExample)
BR (1) BR112017010440A2 (enExample)
CA (1) CA2967659A1 (enExample)
EA (1) EA201791110A1 (enExample)
IL (1) IL252283A0 (enExample)
MX (1) MX2017006454A (enExample)
PH (1) PH12017500933A1 (enExample)
SG (1) SG11201703897SA (enExample)
WO (1) WO2016081466A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
ES2751300T3 (es) 2014-11-21 2020-03-31 Biohaven Therapeutics Ltd Formulación sublingual de riluzol
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
WO2018045217A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US11331303B2 (en) * 2016-09-15 2022-05-17 Skintech Life Science Limited Sublingual or buccal administration of dim for treatment of skin diseases
EP3755332A1 (en) 2018-02-21 2020-12-30 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US10235998B1 (en) * 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
JP2021525714A (ja) * 2018-05-27 2021-09-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． 疾患の処置のためのリルゾール口腔内崩壊錠の使用
JP2021534160A (ja) * 2018-08-16 2021-12-09 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. 疾患処置のためのリルゾール口腔内崩壊錠の使用
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
WO2000074676A1 (en) * 1999-06-04 2000-12-14 Vereniging Voor Christelijk Wetenschappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
WO2013010015A2 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
CA2864008C (en) * 2012-03-01 2020-04-21 Pharnext New compositions for treating amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
JP2017535612A (ja) 2017-11-30
MX2017006454A (es) 2018-03-23
CN107735077A (zh) 2018-02-23
PH12017500933A1 (en) 2017-11-20
IL252283A0 (en) 2017-07-31
AU2015350142A1 (en) 2017-06-15
EA201791110A1 (ru) 2017-11-30
WO2016081466A1 (en) 2016-05-26
EP3220890A1 (en) 2017-09-27
SG11201703897SA (en) 2017-06-29
KR20170137030A (ko) 2017-12-12
US20180153862A1 (en) 2018-06-07
CA2967659A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
BR112017010440A2 (pt) administração sublingual de riluzol
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
BR112017017729A2 (pt) forma de dosagem oral de liberação controlada de agonista de receptor gaba
PH12016501483B1 (en) P-substituted asymmetric ureas and medical uses thereof
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
BR112017009358A2 (pt) imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo
BR112016016098A2 (pt) Compostos orgânicos
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
BR112017028025A2 (pt) complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements